Peptide therapy TikTok claims: what the science actually supports

What did @jacobnach actually say?

The creator, who describes himself as someone who has "treated my body like a lab rat for the last 10 years," laid out three common peptide mistakes: starting with too many compounds at once, expecting fast results, and overdosing based on Reddit advice. He specifically called out tirzepatide users expecting dramatic body changes in under a month, and flagged GHK-Cu at 2mg/day as a dose that's "too high for 90% of people." He framed all of this as hard-won personal experience, not medical guidance. That framing matters, because self-experimentation is not a clinical trial, and what worked or didn't work for one person tells us very little about what will happen in yours.

Does the science back this up?

On the polypharmacy point, he's basically right. Stacking multiple peptides simultaneously makes it impossible to isolate what is causing any effect, good or bad. This is not a controversial position. It's the same logic behind controlled experimental design. The "start low, go slow" principle is well-established in pharmacology and applies whether you're talking about peptides or any other bioactive compound.

On patience and timing, the evidence is more nuanced. Tirzepatide (he calls it "Tessa Morellon") does show meaningful weight loss outcomes in trials, but the timeline he cites is loosely accurate. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), significant body weight reduction became statistically robust at around 12-16 weeks, which roughly aligns with his "day 60 to 90" window, though individual response varies considerably.

On GHK-Cu dosing, the evidence base is thin. GHK-Cu (copper peptide) has shown some interesting results in cell culture and wound healing contexts (Pickart et al., 2015, Journal of Aging Science), but clinical dose-response data in humans is nearly absent. Calling 2mg/day "too high for 90% of people" sounds confident, but that figure appears to come from community consensus, not a clinical study.

What did they get wrong (or right)?

Credit where it is due: the advice to start simple, be patient, and not chase results by doubling doses is genuinely reasonable and consistent with basic pharmacological principles. Most harm in the unregulated peptide space comes from exactly the behaviors he is warning against.

Where he goes wrong is in implying that community-sourced dosing norms, including his own practices, carry clinical authority. Saying "that dose is too high for 90% of people" without citing a single study or clinical source is just one experienced user guessing at population-level pharmacodynamics. It may be correct. It also may not be. The honest answer is that we don't have good human data to say definitively what the right GHK-Cu dose is for most people.

He also casually mentions taking 15 peptides himself while advising beginners to take one or two. That contradiction is worth naming. There is no rigorous safety or efficacy data on stacking 15 peptides simultaneously. Normalizing that for a 69,000-person audience carries real risk, even if the immediate advice is "don't do what I do."

What should you actually know?

Most peptides discussed in communities like this one, including GHK-Cu, BPC-157, and others in the same category, are not FDA-approved for the uses being described. That does not automatically make them dangerous, but it does mean the dosing guidance floating around online is largely derived from animal studies, small case series, and user reports rather than controlled human trials.

The one compound he references with actual robust clinical data is tirzepatide, which is an FDA-approved drug with a defined prescribing framework. If you are interested in it, that conversation belongs with a licensed clinician, not a TikTok comment section.

The broader point he makes about impatience driving misuse is supported by behavioral research in supplement and drug use contexts. People who don't see quick results often escalate doses, which increases adverse event risk without necessarily improving outcomes (Faasse and Petrie, 2013, BMJ). That mechanism is real and worth taking seriously regardless of the specific compound involved.